Session Chair Profile
Ph.D., Director, Healthcare Ventures, GE Ventures
Alex de Winter invests in life science instrumentation and clinical diagnostics startups, leading GE Ventures’ investment in Veracyte (VCYT). Alex joined GE Ventures from Mohr Davidow Ventures, where he served as a board director with On-Q-ity and board observer for CardioDx, Corventis, Crescendo Bioscience, didimi, DVS Sciences, and Personalis. He started his career as a research scientist with 454 Life Sciences (acquired by Roche) and Pacific Biosciences (PACB). Alex has an MBA from UC Berkeley, a Ph.D. in chemistry from Stanford, and graduated magna cum laude from Amherst College with a BA in English and Chemistry. When not working, Alex enjoys cooking and supporting/lamenting the Dallas Cowboys.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Disruptive technologies often face hurdles in gaining acceptance and adoption in an already busy marketplace. This session will be instructive in developing a clear product, company message and commercialization strategy, which are “must haves” to successfully commercialize an advanced technology that will revolutionize health care and precision medicine, in particular.